New combo therapy aims to slow deadly pancreatic cancer
NCT ID NCT04331041
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding a drug called defactinib to targeted radiation therapy can help control advanced pancreatic cancer better than radiation alone. About 42 people with inoperable pancreatic cancer will take part. The goal is to see if the combination slows cancer growth and is safe.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER OF THE PANCREAS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill rouse the immune system against pancreatic cancer?
- Can a new ultrasound technique spot hidden pancreatic cancers earlier?
- A simple breath test might spot multiple cancers before symptoms appear
- Can High-Dose vitamin c boost Chemo's punch against pancreatic cancer?
- Can High-Dose vitamin c boost chemo against pancreatic cancer?
- Could a simple blood test catch pancreatic cancer before It's too late?